Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to announce ($1.29) earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from ($1.55) to ($0.92). Agios Pharmaceuticals reported earnings of ($0.59) per share during the same quarter last year, which would indicate a negative year over year growth rate of 118.6%. The firm is expected to issue its next earnings results on Thursday, April 29th.
On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($5.79) per share for the current year, with EPS estimates ranging from ($6.17) to ($5.45). For the next fiscal year, analysts forecast that the company will post earnings of ($6.73) per share, with EPS estimates ranging from ($10.20) to ($4.39). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, February 24th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.31) by ($0.10). The firm had revenue of $39.10 million for the quarter, compared to the consensus estimate of $39.86 million. Agios Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 170.65%. The business’s revenue was up 10.5% on a year-over-year basis. During the same period last year, the company posted ($1.60) EPS.
In other Agios Pharmaceuticals news, insider Darrin Miles sold 2,200 shares of the stock in a transaction on Monday, March 1st. The shares were sold at an average price of $47.99, for a total transaction of $105,578.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.16% of the company’s stock.
Several large investors have recently bought and sold shares of the company. First Trust Advisors LP lifted its position in shares of Agios Pharmaceuticals by 0.9% in the 4th quarter. First Trust Advisors LP now owns 1,822,381 shares of the biopharmaceutical company’s stock worth $78,964,000 after purchasing an additional 16,839 shares during the period. Norges Bank purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth about $24,691,000. Point72 Asset Management L.P. lifted its position in shares of Agios Pharmaceuticals by 43.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 477,852 shares of the biopharmaceutical company’s stock worth $16,725,000 after purchasing an additional 144,593 shares during the period. Morgan Stanley lifted its position in shares of Agios Pharmaceuticals by 782.9% in the 3rd quarter. Morgan Stanley now owns 443,708 shares of the biopharmaceutical company’s stock worth $15,532,000 after purchasing an additional 393,452 shares during the period. Finally, Nuveen Asset Management LLC lifted its position in shares of Agios Pharmaceuticals by 14.6% in the 4th quarter. Nuveen Asset Management LLC now owns 427,561 shares of the biopharmaceutical company’s stock worth $18,526,000 after purchasing an additional 54,487 shares during the period. 92.93% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:AGIO opened at $52.84 on Thursday. The company’s fifty day moving average price is $50.51 and its 200-day moving average price is $44.18. The firm has a market capitalization of $3.68 billion, a price-to-earnings ratio of -10.72 and a beta of 1.80. Agios Pharmaceuticals has a one year low of $32.47 and a one year high of $58.93.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.
Featured Article: Percentage Decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.